Brokerages Anticipate Sanofi (NASDAQ:SNY) Will Announce Quarterly Sales of $11.44 Billion

Share on StockTwits

Wall Street analysts expect Sanofi (NASDAQ:SNY) to announce $11.44 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Sanofi’s earnings. The lowest sales estimate is $11.22 billion and the highest is $11.66 billion. Sanofi posted sales of $10.64 billion in the same quarter last year, which would indicate a positive year over year growth rate of 7.5%. The business is expected to report its next earnings report on Thursday, February 4th.

According to Zacks, analysts expect that Sanofi will report full year sales of $44.80 billion for the current financial year, with estimates ranging from $43.83 billion to $45.39 billion. For the next financial year, analysts forecast that the firm will report sales of $46.02 billion, with estimates ranging from $44.92 billion to $46.81 billion. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Sanofi.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, October 29th. The company reported $1.07 EPS for the quarter, missing the Zacks’ consensus estimate of $1.08 by ($0.01). The firm had revenue of $11.08 billion for the quarter, compared to analysts’ expectations of $11.82 billion. Sanofi had a return on equity of 24.71% and a net margin of 13.88%.

SNY has been the topic of several research analyst reports. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Sanofi in a research report on Friday, October 30th. Zacks Investment Research upgraded Sanofi from a “hold” rating to a “buy” rating and set a $53.00 price target on the stock in a research note on Monday, October 19th. Morgan Stanley reissued an “overweight” rating on shares of Sanofi in a report on Friday, January 8th. BidaskClub upgraded shares of Sanofi from a “strong sell” rating to a “sell” rating in a research report on Friday, December 18th. Finally, The Goldman Sachs Group began coverage on Sanofi in a report on Sunday, October 4th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $55.67.

SNY traded down $0.31 on Wednesday, reaching $48.04. The company’s stock had a trading volume of 3,831,383 shares, compared to its average volume of 3,124,141. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.85 and a quick ratio of 1.38. The business’s 50 day moving average is $47.97 and its 200 day moving average is $49.34. Sanofi has a 1 year low of $37.62 and a 1 year high of $55.00. The stock has a market cap of $120.30 billion, a price-to-earnings ratio of 21.26, a price-to-earnings-growth ratio of 1.85 and a beta of 0.51.

A number of institutional investors have recently modified their holdings of the business. Sei Investments Co. raised its stake in Sanofi by 1.6% during the third quarter. Sei Investments Co. now owns 340,509 shares of the company’s stock valued at $17,081,000 after purchasing an additional 5,316 shares in the last quarter. Brinker Capital Investments LLC purchased a new stake in shares of Sanofi during the 3rd quarter valued at $4,912,000. Envestnet Asset Management Inc. raised its position in Sanofi by 3.1% in the 3rd quarter. Envestnet Asset Management Inc. now owns 543,419 shares of the company’s stock worth $27,263,000 after purchasing an additional 16,180 shares during the period. Toronto Dominion Bank purchased a new position in Sanofi in the 2nd quarter worth $54,000. Finally, JPMorgan Chase & Co. raised its position in Sanofi by 26.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 235,554 shares of the company’s stock worth $11,896,000 after purchasing an additional 48,543 shares during the period. 7.15% of the stock is owned by institutional investors and hedge funds.

Sanofi Company Profile

Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura.

See Also: Dead Cat Bounce

Get a free copy of the Zacks research report on Sanofi (SNY)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Sanofi (NASDAQ:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with's FREE daily email newsletter.